Get the Stockscreener App
4.29
10.44%
-0.50
After Hours:
4.27
-0.02
-0.47%
Exagen Inc stock is traded at $4.29, with a volume of 368.97K.
It is down -10.44% in the last 24 hours and up +38.83% over the past month.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
See More
Previous Close:
$4.79
Open:
$4.68
24h Volume:
368.97K
Relative Volume:
0.90
Market Cap:
$103.65M
Revenue:
$68.38M
Net Income/Loss:
$-20.17M
P/E Ratio:
-4.8535
EPS:
-0.8839
Net Cash Flow:
$-14.13M
1W Performance:
-13.86%
1M Performance:
+38.83%
6M Performance:
-40.42%
1Y Performance:
-40.33%
1-Day Range:
$4.25
$4.68
1-Week Range:
$4.25
$5.55
52-Week Range:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.29 | 115.73M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen study shows lupus test identifies 25% more patients - Investing.com
Lupus test used on 1M patients finds cases routine lab work misses - Stock Titan
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock Declines - The Legal Advocate
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05% - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Yahoo Finance
Parian Ultreia reports 5.3% stake in Exagen (NASDAQ: XGN) - Stock Titan
Exagen Inc. Q1 2026 Earnings: EPS Beat Surprises, but Revenue Details AbsentEstimate Accuracy - The Legal Advocate
XGN Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Revenue UncertaintyEarnings Weakness Phase - Newser
Exagen Inc. (XGN) Holds Steady Near Support Amid Low VolatilityLiquidity Sweep - The Legal Advocate
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Institutional Volume - The Legal Advocate
William Blair Maintains Exagen(XGN.US) With Buy Rating - Moomoo
Exagen Inc. Common Stock (XGN) Stock Price Today & Analysis - Gotrade
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Per Share - Newser
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc stock (US30063K1051): 13G filing shows 9.9% stake - AD HOC NEWS
EXAGEN (XGN) holder Jorey Chernett reports 2.41M shares, 9.9% - Stock Titan
Exagen (XGN) Rallies +8.02% as Bulls Target $3.96 2026-05-19Professional Trade Ideas - Newser
Exagen (XGN) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsEarnings Deceleration Risk - newsline.com
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Why Exagen (XGN) Just Dropped -4.55% — What to Watch 2026-05-15TPO Profile - Newser
Exagen Company Profile & Introduction - Moomoo
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Exagen (XGN) Receives a Buy from BTIG - The Globe and Mail
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Liquidia Technologies (LQDA) - The Globe and Mail
Exagen (XGN) Q1 2026 Earnings Transcript - AOL.com
Exagen Inc stock (US30063K1051): Q1 revenue hits record $17.3M, up 12% - AD HOC NEWS
XGN Maintained by BTIG -- Price Target Lowered to $8.00 - GuruFocus
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
BTIG Maintains Exagen(XGN.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Exagen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exagen stock price target lowered to $8 by BTIG on valuation - Investing.com UK
Exagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid Challenges - GuruFocus
Exagen (XGN) Reports Record Q1 Revenue of $17.3 Million, Up 12% Year-Over-Year - GuruFocus
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):